Clinical trial NCT05664100: First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss
Official title: A Phase 1b, Prospective, Randomized, Single-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety of FX-345 Administered as a Single Intratympanic Injection in Adults With Acquired Adult-Onset Sensorineural Hearing Loss
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Hearing Loss, Sensorineural
Keywords: Hearing loss
Intratympanic Injection
Lead sponsor: Frequency Therapeutics
Sponsor class: INDUSTRY
First posted: 2022-12-23
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 67
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This single-blind, placebo-controlled trial will be conducted to evaluate the safety of FX-345 administered as a single intratympanic injection in adults with acquired sensorineural hearing loss. The primary objectives are to assess the local safety, systemic safety, and pharmacokinetic (PK) profile to determine systemic exposure.

Detailed description: This study will enroll two cohorts. Cohort 1 (n=9) will be enrolled first to rapidly assess safety and drug exposure. After the sponsor completes an unblinded safety review, Cohort 2 (n=27) will be enrolled to continue safety evaluation of FX-345.

Eligibility criteria: Inclusion Criteria:

* Adult aged 18-67 years (inclusive)
* Documented medical history consistent with acquired, adult onset, sensorineural hearing loss
* At the Screening, Lead-in (Visit 2) and Treatment (Day 1) Visits, a pure tone average of 40- 80 dBHL at 500Hz, 1000Hz, 2000Hz, and 4000Hz in the potential study ear to be injected
* Female participants must not be pregnant, breastfeeding, or lactating. Women of child-bearing potential must agree to use a highly effective contraceptive method and must have a negative urine pregnancy test.
* Male participants must refrain from donating sperm and agree to be either abstinent or use a barrier method of contraception

Exclusion Criteria:

* Randomization in a FX-322 (laduviglusib and sodium valproate) clinical trial
* Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube.
* Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear at the Screening, Lead-in (Visit 2) or Treatment (Day 1) Visits, based on the investigator's judgment.
* Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected.
* Within 3 months of screening visit any of the following: 1) an intratympanic injection in either ear 2) treatment with steroids 3) onset of sudden sensorineural hearing loss
* Evidence of or previous diagnosis of traumatic brain injury, Meniere's disease, or genetic hearing loss
* History of head or neck radiation, significant systemic autoimmune disease, and/or chronic, recurrent clinically significant vestibular symptoms
* Exposure to another investigational drug within 28 days prior to screening visit

Primary outcomes:
measure: Number of Participants With Treatment-emergent Adverse Event(s) (TEAEs)
timeFrame: Baseline Through Day 90
measure: Cmax
timeFrame: Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose
measure: AUClast
timeFrame: Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose
measure: CL/F
timeFrame: Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose
measure: Vss
timeFrame: Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose
measure: t1/2
timeFrame: Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose
measure: Tmax
timeFrame: Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose
measure: Elimination rate constant
timeFrame: Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
city: Sarasota
country: United States
facility: Clinical Trial Site
state: Florida
city: Spartanburg
country: United States
facility: Clinical Trial Site
state: South Carolina
city: San Antonio
country: United States
facility: Clinical Trial Site
state: Texas
city: San Antonio
country: United States
facility: Clinical Trial Site
state: Texas
Study officials:
affiliation: Frequency Therapeutics
name: Carl LeBel, PhD
role: STUDY_DIRECTOR
References: